Condition 1: depression. Condition 2: Multiple sclerosis. Recurrent depressive disorder Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group receive zinc sulfate (220 mg containing 50 mg zinc, Alhavi pharmaceutical co .Iran) daily for 12 weeks. Intervention 2: Control group receive placebo.
Treatment - Drugs
Placebo
Intervention group receive zinc sulfate (220 mg containing 50 mg zinc, Alhavi pharmaceutical co .Iran) daily for 12 weeks.
Control group receive placebo.
Sponsors
Kurdistan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: having major depressive disorder based on the beck questionnaire with a score of 19; MS patients according to clinical and paraclinical findings. Exclusion criteria: having a personality disorder; Education below than elementary fifth; symptoms of a psychotic disorder; other neurological disorders except MS; Serious disease including renal failure, hepatic insufficiency, ischemic heart disease, cancer, endocrine and metabolic diseases based on clinical records.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Muscle strength. Timepoint: baseline the study and after three months. Method of measurement: scoring 0-5.;Balance. Timepoint: baseline the study and after three months. Method of measurement: examination (Romberg test,Tandem gate test).;Depression. Timepoint: baseline the study and after three months. Method of measurement: Beck Depression Inventory.;Nystagmus. Timepoint: baseline the study and after three months. Method of measurement: examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoheila Salari
Kurdestan University of Medical Sciences
Outcome results
None listed